Will Biogen Idec Inc. Rule Biotech in 2014?

The biotech sector's endured an up-and-down 2014 after the immense gains captured in 2013's market rise, but don't tell that to fast-rising Biogen Idec (NASDAQ: BIIB  ) . Biogen's stock has roared higher by more than 10% in 2014 after experiencing a tremendous run-up last year, topping the charts among big biotech stocks and giving hope to investors across the industry. Biogen's hit a home run with multiple sclerosis drug Tecfidera, which reeled in nearly $400 million in sales in the past quarter, but this company's not sitting still waiting for its next big success story.

Biogen scored again for investors recently when the Food and Drug Administration approved the company's developmental hemophilia B treatment Alprolix. While Biogen's relatively inexperienced in the hemophilia market, it's gearing up for a big push, and Alprolix is the first stepping stone to Biogen's plans for dominance in a market that heavyweights such as Pfizer (NYSE: PFE  ) and Bayer (NASDAQOTH: BAYRY  ) are fighting for.

Can Biogen score another investor success from the hemophilia market? Find out all about Alprolix's success -- and what Biogen plans to do for an encore -- in the video below as Motley Fool contributor Dan Carroll takes you through the latest in one of big biotech's hottest stocks.

Will Biogen top the charts in 2014?
Biogen's laid out an outstanding performance for investors lately, but one maxim's true in the markets: There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (2) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 07, 2014, at 10:14 AM, RideWildfire wrote:

    Great news for patients needing these treatments, but are there enough to be big revenue generators?

  • Report this Comment On April 14, 2014, at 1:07 AM, AvmanM wrote:

    Just a week later, the Motley Fool publishes an article titled "Why Biogen Idec Inc., Vertex Pharmaceuticals Incorporated, and Broadcom Corp. Are Today’s 3 Worst Stocks". Which is it, Fool?

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2899739, ~/Articles/ArticleHandler.aspx, 9/2/2015 11:12:29 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dan Carroll

Dan began writing for the Motley Fool in 2012. He is a health care specialist who also follows the defense industry along with tracking the broader U.S. and international markets.

Today's Market

updated Moments ago Sponsored by:
DOW 16,166.25 107.90 0.67%
S&P 500 1,925.00 11.15 0.58%
NASD 4,670.75 34.64 0.75%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/2/2015 10:57 AM
BIIB $297.70 Up +5.20 +1.78%
Biogen Idec CAPS Rating: ****
BAYRY $132.77 Up +1.92 +1.47%
Bayer AG (ADR) CAPS Rating: ****
NVO $54.88 Up +0.68 +1.26%
Novo Nordisk CAPS Rating: *****
PFE $31.60 Up +0.24 +0.77%
Pfizer CAPS Rating: ****